The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center

INTRODUCTION: Eculizumab is a complement inhibitor used in treating atypical hemolytic uremic syndrome (aHUS). This study showcases patient demographics, clinical and laboratory results of these patients, and overall outcomes of patients with aHUS treated with eculizumab. METHODS: The authors conduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Katharine, Ananthula, Aneesha, Lopez-Flores, Ruby, del Toro, Alejandra, Chapple, Andrew G, Loch, Michelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Permanente Federation 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266857/
https://www.ncbi.nlm.nih.gov/pubmed/36718583
http://dx.doi.org/10.7812/TPP/22.073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266857/
https://www.ncbi.nlm.nih.gov/pubmed/36718583
http://dx.doi.org/10.7812/TPP/22.073

Ejemplares similares